Original Research J Clin Psychiatry February 2026

Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis of Adverse Events and Technological Advancements

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary TMS is now used far beyond tightly controlled trials, including in patients with complex psychiatric comorbidity and expanding off-label indications. As clinical exposure grows, psychiatrists need real-world safety data on what gets reported after treatment, not just what appears in efficacy studies. FAQ What did this study find about the overall safety pattern of transcranial magnetic stimulation in FDA MAUDE reports? 11 questions
Key Takeaways MAUDE reporting accelerated after 2021, with 45 reports in 2022, 41 in 2023, and 45 in 2024, suggesting that clinicians may encounter more postmarketing safety signals as TMS use expands across approved and off-label indications. 6 takeaways Clinical Guide How should clinicians monitor patients receiving transcranial magnetic stimulation for clinically important adverse effects? 7 steps Clinical Guide How should clinicians document and report adverse events during transcranial magnetic stimulation to improve safety surveillance? 5 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe